Memorial Sloan Kettering Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
Not Applicable
Completed
- Conditions
- Fallopian Tubes CancerOvarian CancerPeritoneal Cancer
- Interventions
- Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01223235
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Phase 3
Active, not recruiting
- Conditions
- MelanomaCNS-Spinal CD/MEMBR, NOSSoft TissueSarcomaLymph NodesOvarian CancerBone
- Interventions
- Radiation: IGIMRT using a single dose of 24 GyRadiation: IGIMRT 27 Gy in 3 fractions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT01223248
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇮🇹University of Pisa, Pisa, Italy
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
Not Applicable
Completed
- Conditions
- Gastric CancerLung Cancer
- Interventions
- Procedure: respiration correlated CT scan
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT01213004
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Phase 2
Completed
- Conditions
- SarcomaLiposarcoma
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT01209598
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Radiation: multiple beams utilizing either intensity-modulated or 3D-conformal techniques
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT01203839
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (Follow-up Only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk (Follow-up Only), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Bergen (Follow-up Only), Montvale, New Jersey, United States
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Phase 4
Completed
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 113
- Registration Number
- NCT01200355
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins
Not Applicable
Completed
- Conditions
- Rectal Cancer
- Interventions
- Procedure: Eppendorf hypoximeter
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01189877
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT01189435
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Early Phase 1
Active, not recruiting
- Conditions
- SarcomaDesmoplastic Small Round Cell Tumor (DSRCT)
- Interventions
- Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT01189643
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
Not Applicable
Completed
- Conditions
- Ascites
- Interventions
- Behavioral: McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01188746
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States